12-2414-cv

ONY, Inc. v. Cornerstone Therapeutics, Inc.

UNITED STATES COURT OF APPEALS

FOR THE SECOND CIRCUIT

 

August Term, 2012

(Argued: April 25, 2013 Decided: June 26, 2013)

Docket No. 12-2414-cv

 

ONY, INC.,

Plaintiff-Appellant,

— v. — 

CORNERSTONE THERAPEUTICS, INC., CHIESI FARMACEUTICI S.P.A., RANGASAMY

RAMANATHAN, M.D., JATINDER J. BHATIA, M.D., KRISHNAMURTHY C. SEKAR, M.D.,

Defendants-Appellees,

NATURE AMERICA, INC. DBA NATURE PUBLISHING GROUP, EDWARD E. LAWSON, M.D.,

AMERICAN ACADEMY OF PEDIATRICS, PREMIER, INC. DBA PREMIER RESEARCH SERVICES,

FRANK R. ERNST, PHARM.D.,

Defendants.

*

 

B e f o r e:

WINTER, CALABRESI, and LYNCH, Circuit Judges.

__________________

*

 The Clerk of the Court is directed to amend the official caption in the case to

conform to the caption listed above.
Appeal from a May 21, 2012 judgment of the United States District Court for the

Western District of New York (William M. Skretny, C.J.) dismissing plaintiff’s complaint

in its entirety. Defendants are various corporate sponsors, authors, and publishers of a

scientific journal article comparing the effectiveness of several types of surfactants. 

Plaintiff complains that the article – and the distribution of selections from it – violates

the Lanham Act and New York General Business Law § 349, and also constitutes tortious

injurious falsehood and interference with prospective economic advantage. The district

court correctly concluded that plaintiff has failed to state a claim based on publication of

the article itself because the challenged statements are protected scientific opinion. We

further conclude that plaintiff has failed adequately to allege that defendants Chiesi and

Cornerstone distributed misleading excerpts of the article. 

AFFIRMED.

 

MITCHELL J. BANAS, JR., of counsel, Jaeckle Fleischmann & Mugel, LLP,

Buffalo, New York, for plaintiff-appellant.

J. KEVIN FEE (Kristin H. Altoff, Jordana S. Rubel, on the brief), Morgan,

Lewis & Bockius, Washington, D.C., for defendants-appellees.

 

2
GERARD E. LYNCH, Circuit Judge:

This case asks us to decide when a statement in a scientific article reporting

research results can give rise to claims of false advertising under the Lanham Act,

deceptive practices under New York General Business Law § 349, and the common-law

torts of injurious falsehood and interference with prospective economic advantage. We

conclude that, as a matter of law, statements of scientific conclusions about unsettled

matters of scientific debate cannot give rise to liability for damages sounding in

defamation. We further conclude that the secondary distribution of excerpts of such an

article cannot give rise to liability, so long as the excerpts do not mislead a reader about

the conclusions of the article. 

BACKGROUND

The following factual background is taken from the complaint, whose allegations

we accept as true, and from the materials referenced in the complaint. Plaintiff ONY, Inc.

(“ONY”) and defendant Chiesi Farmaceutici, S.p.A. (“Chiesi”) are two of the biggest

producers of surfactants, biological substances that line the surface of human lungs. 

Surfactants are critical to lung function: they facilitate the transfer of oxygen from inhaled

air into the blood stream.1

 Although the human body naturally produces surfactants,

1

 Surfactants do this by lowering the surface tension of the liquid surface of

alveoli, the air sacs that serve as the venue for oxygen exchange. Surfactants also help to

ensure that the alveoli inflate evenly and do not overinflate. 

3
prematurely born infants often produce inadequate surfactant levels. Infants with such a

deficiency are at a higher risk for lung collapse and Respiratory Distress Syndrome

(“RDS”), a condition that can result in respiratory failure and death. The non-human

surfactants produced and sold by, among others, ONY and Chiesi are the primary

treatment for RDS. The FDA has approved three surfactants for treatment of RDS in neonatal infants. ONY produces one derived from bovine lung surfactant that bears the trade

name “Infasurf.” Chiesi produces a competing surfactant derived from porcine lung

mince that goes by “Curosurf.”2 Chiesi, an Italian pharmaceutical firm, contracts with its

co-defendant Cornerstone Therapeutics, Inc. (“Cornerstone”) to distribute and market

Curosurf in the United States. 

The parties vigorously contest the relative effectiveness of their products – in the

marketplace, in the scientific literature, and in the instant lawsuit. The parties agree that

two variables are particularly relevant to this comparison: mortality rate and length of

stay. Mortality rate means the percentage of infants treated with a particular surfactant

who do not survive. Length of stay refers to the amount of time an infant remains in the

hospital for treatment. These two variables are not entirely independent: in some cases

the length of stay is shortened by death, which is reflected in the mortality rate. Put

differently, some of the same causes of increased mortality rate (low birth weight, shorter

2

 The third surfactant, “Survanta,” which is produced from bovine lung mince, is

manufactured by Abbott Pharmaceuticals, which is not a party to this lawsuit. 

4
gestational period) also cause shorter lengths of stay. Conversely, infants with shorter

hospitalization might have had less serious medical conditions from the beginning,

independent of treatment variables. At the same time, a particularly effective drug may

both reduce mortality rate and shorten length of stay. 

In 2006, as part of its effort to promote and sell Curosurf, Chiesi hired defendant

Premier, Inc. (“Premier”) to build a database and conduct a study of the relative

effectiveness of the different surfactants. Premier engaged one of its employees, Frank

Ernst, to carry out the necessary technical work. Chiesi then hired several medical

doctors, including defendants Rangasamy Ramanathan, Jatinder J. Bhatia, and

Krishnamurthy Sekar (the “physician defendants”), to present findings based on

Premier’s database at various medical conferences. Specifically, the physician defendants

presented findings at the May 2007 annual meeting of the Pediatric Academic Societies

that Curosurf was associated with a 20% lower mortality rate than either Infasurf or

Survanta. At the October 2007 annual meeting of the European Pediatric Society, the

physician defendants, along with Ernst and others, presented additional findings;

specifically, they presented evidence showing that Curosurf was associated with a 15%

shorter length of stay than either Infasurf or Survanta. Despite the differences between

the data presented at the two conferences, both presentations were based on the same data

set, namely the one compiled by Premier and Ernst.

5
In 2011, the physician defendants, along with Ernst, eventually decided to publish

some of the findings from the same data set in a peer-reviewed journal. They submitted

their article to the Journal of Perinatology, the leading journal in the field of neonatology,

which is the study of newborn infants.3

 The article was published in the September 1,

2011 volume of the journal after being peer reviewed by two anonymous referees. See R.

Ramanathan et al., Mortality in Preterm Infants with Respiratory Distress Syndrome

Treated with Poractant Alfa, Calfactant or Beractant: A Retrospective Study, 33 J.

Perinatology 119 (2011). 

According to ONY, the article contains five distinct incorrect statements of fact

about the relative effectiveness of Curosurf versus Infasurf: (1) that Infasurf “was

associated with a 49.6% greater likelihood of death than” Curosurf; (2) that Curosurf

“treatment for RDS was associated with a significantly reduced likelihood of death when

compared with” Infasurf; (3) that the authors’ “model found [Infasurf] to be associated

with a significantly greater likelihood of death than” Curosurf; (4) that the authors’ study

showed “a significant greater likelihood of death with” Infasurf than Curosurf; and (5) the

summary concluding sentence:

In conclusion, this large retrospective study of preterm infants

with RDS found lower mortality among infants who received

3

 The Journal of Perinatology is also the official journal of the Section of Perinatal

Pediatrics of the American Academy of Pediatrics, the leading pediatrics organization in

the United States.

6
[Curosurf], compared with infants who received either

[Infasurf] or [Survanta], even after adjusting for patient

characteristics such as gestational age and [birth weight], and

after accounting for hospital characteristics and center effects.

Id.; Proposed Am. Compl. ¶ 35. Plaintiff also alleges that the circumstances surrounding

the article’s publication were unusual: Bhatia is an Associate Editor, and Sekar is a

member of the editorial board, of the Journal of Perinatology. Plaintiff alleged in its

complaint that one of the two peer reviewers objected to its publication, but the other peer

reviewer recommended the article for publication, and the Editor-in-Chief broke the tie. 

Plaintiff does not allege, however, that the publication of the article based on the

affirmative opinions of one reviewer and the Editor-in-Chief was a departure from

accepted or customary procedure. Further, the article was published in an “open access”

format, which allows it to be viewed electronically by the general public without paying

the typically applicable fee or ordering a subscription; the fees associated with such

publication were paid by Chiesi and Cornerstone. 

The article’s conclusions were not unqualified. The authors considered the

objection that the retrospective nature of the study might cause a disparity between the

groups included in the study. More specifically, the authors noted that the article’s

finding may “most likely . . . be due to different surfactant doses administered to the

infants included in the database,” because Curosurf was, on average, prescribed in higher

doses than its competitors. Finally, the authors disclosed that the study was sponsored by

7
Chiesi, that Ernst was an employee of Premier, that Chiesi hired Premier to conduct the

study, and that all three physician defendants had served as consultants to Chiesi. 

Plaintiff’s primary objection to the substance of the article’s scientific

methodology is that the authors omitted any mention of the length-of-stay data, despite

the fact that they had presented such data at the October 2007 conference. Because an

important determinant of mortality rate is the pre-treatment health of the infants in the

sample, plaintiff contends that the omission of length-of-stay data was intentional and

designed to mask the fact that the neonatal infants treated with Curosurf had a greater ex

ante chance of survival than did the group treated with Infasurf. If the length-of-stay data

had been included, plaintiff alleges, “it would be obvious to readers that the differences in

the results were a result of differences in the groups of patients treated, not of any

differences in the effect of the particular lung surfactant administered.” Appellant’s Br. at

14. Plaintiff also objects to the authors’ failure to cite articles with different primary

conclusions, although such contradictory authority was known to them, and to the use of

retrospective data, which was allegedly improper because it rendered the data subject to

“selective distortion.” Id. at 10. Finally, plaintiff contends that Chiesi and Cornerstone

paid Premier to collect data that supported their own product’s effectiveness.

After the article’s publication, Chiesi and Cornerstone issued a press release

touting its conclusions and distributed promotional materials that cited the article’s

findings. Since the article’s publication, meanwhile, plaintiff has, through its corporate

8
officers – themselves pediatricians – written letters to the Journal of Perinatology

rebutting the article’s conclusions, objecting to its methods, and asking that it be

retracted. We take judicial notice of the fact that several of those letters were eventually

published by the journal, although they did not appear in print until after the district court

dismissed the complaint. See J.J. Cummings, Is There Evidence for a Mortality

Difference Between Natural Surfactants?, 33 J. Perinatology 161 (2013) (originally

published online, Feb. 16, 2012); see also E.A. Egan, In Response to Mortality in Preterm

Infants with Respiratory Distress Syndrome Treated with Poractant Alfa, Calfactant or

Beractant: A Retrospective Study, 33 J. Perinatology 165 (2013). The authors were

given, and took, the opportunity to respond to those letters. See R. Ramanathan et al.,

Response to Dr. Egan’s Letter, 33 J. Perinatology 166 (2013).

On December 2, 2011, plaintiff filed a complaint seeking damages and injunctive

relief in the United States District Court for the Western District of New York. The

complaint alleged violations of the Lanham Act and New York General Business Law

§ 349, as well as claims for injurious falsehood and tortious interference with prospective

economic advantage.4

 Defendants moved to dismiss the complaint in its entirety; plaintiff

4

 Although plaintiff originally pled its tortious interference claim as interference

with existing contracts, it admitted before the district court that the complaint did not

plead interference with any particular contract, and did not seek leave to amend these

allegations. The district court therefore treated this claim as one alleging tortious

interference with prospective economic advantage. We adopt the same approach. 

9
cross-moved to amend its complaint and proposed an amended complaint. The district

court (William M. Skretny, Chief Judge) granted the motion to dismiss and denied as

futile plaintiff’s cross-motion to amend. Judgment was entered on May 21, 2012, and

plaintiff timely appealed.

DISCUSSION

We review a district court’s dismissal of a complaint for failure to state a claim de

novo. Sarmiento v. United States, 678 F.3d 147, 152 (2d Cir. 2012). We accept as true

all factual allegations contained in the complaint. Id. We also review a district court’s

interpretation of a statute or state common law de novo. Roach v. Morse, 440 F.3d 53, 56

(2d Cir. 2006); Reilly v. NatWest Mkts. Grp. Inc., 181 F.3d 253, 262 (2d Cir. 1999). 

I. Claims Arising out of the Article’s Publication

The Lanham Act generally prohibits false advertising. In particular, it provides a

civil cause of action against “any person” who, in interstate commerce, “uses . . . any . . .

false or misleading description of fact, or false or misleading representation of fact.” 15

U.S.C. § 1125(a)(1). Because the Act proscribes conduct that, but for its false or

misleading character, would be protected by the First Amendment, free speech principles

inform our interpretation of the Act. Indeed, “we have been careful not to permit

overextension of the Lanham Act to intrude on First Amendment values.” Boule v.

Hutton, 328 F.3d 84, 91 (2d Cir. 2003) (internal quotation marks omitted). We have been

especially careful when applying defamation and related causes of action to academic

10
works, because academic freedom is “a special concern of the First Amendment.” 

Keyishian v. Bd. of Regents of the Univ. of the State of N.Y., 385 U.S. 589, 603 (1967). 

Generally, statements of pure opinion – that is, statements incapable of being

proven false – are protected under the First Amendment. Milkovich v. Lorain Journal

Co., 497 U.S. 1, 19-20 (1990); see also Groden v. Random House, Inc., 61 F.3d 1045,

1051-52 (2d Cir. 1995). But the line between fact and opinion is not always a clear one. 

In Milkovich, the Supreme Court declined to carve out an absolute privilege for

statements of opinion and reaffirmed that the test for whether a statement is actionable

does not simply boil down to whether a statement is falsifiable. 497 U.S. at 18. To

illustrate the difficulty, the Court provided the example of a statement of fact phrased as a

statement of opinion: stating that “in my opinion John Jones is a liar” is no different from

merely asserting that John Jones is a liar. Id. at 18-19. Thus, the question of whether a

statement is actionable admits of few easy distinctions. 

In this case, plaintiff claims that the article made statements about scientific

findings that were intentionally deceptive and misleading, and that it therefore constituted

false advertising. Plaintiff’s theory is that scientific claims made in print purport to be

statements of fact that are falsifiable, and such statements can be defamatory or represent

false advertising if known to be false when made. Plaintiff argues that the district court

based its conclusion that the article’s statements were non-actionable solely on its

determination that the assertions were statements of opinion, without conducting the more

11
fine-grained analysis required by Milkovich. According to plaintiff, dismissal prior to

discovery under such circumstances was error. 

Scientific academic discourse poses several problems for the fact-opinion

paradigm of First Amendment jurisprudence. Most conclusions contained in a scientific

journal article are, in principle, “capable of verification or refutation by means of

objective proof,” Phantom Touring, Inc. v. Affiliated Publ’ns, 953 F.2d 724, 728 n.7 (1st

Cir. 1992). Indeed, it is the very premise of the scientific enterprise that it engages with

empirically verifiable facts about the universe. At the same time, however, it is the

essence of the scientific method that the conclusions of empirical research are tentative

and subject to revision, because they represent inferences about the nature of reality based

on the results of experimentation and observation. Importantly, those conclusions are

presented in publications directed to the relevant scientific community, ideally in peerreviewed academic journals that warrant that research approved for publication

demonstrates at least some degree of basic scientific competence. These conclusions are

then available to other scientists who may respond by attempting to replicate the

described experiments, conducting their own experiments, or analyzing or refuting the

soundness of the experimental design or the validity of the inferences drawn from the

results. In a sufficiently novel area of research, propositions of empirical “fact” advanced

in the literature may be highly controversial and subject to rigorous debate by qualified

experts. Needless to say, courts are ill-equipped to undertake to referee such

12
controversies. Instead, the trial of ideas plays out in the pages of peer-reviewed journals,

and the scientific public sits as the jury. 

In other cases involving “matters of argument” appearing in print, we have been

reluctant to recognize causes of action grounded on statements of fact that are best

evaluated by an informed reader. In Groden, we concluded that “statements made to

summarize an argument or opinion within a book” are “to be accepted or rejected by

those who read the book,” even when such statements are made in advertisements. 61

F.3d at 1052. The Seventh Circuit has also declined to allow suits based on claims of

false conclusions in matters of scientific controversy to proceed. See Underwager v.

Salter, 22 F.3d 730, 736 (7th Cir. 1994) (“Scientific controversies must be settled by the

methods of science rather than by the methods of litigation. . . . More papers, more

discussion, better data, and more satisfactory models – not larger awards of damages –

mark the path toward superior understanding of the world around us.”). District courts

presented with controversial scientific questions have also declined to find them

actionable. See Arthur v. Offit, No. 01:09-cv-1398, 2010 WL 883745, at *6 (E.D. Va.

March 10, 2010) (“Plaintiff’s claim . . . threatens to ensnare the Court in [a] thorny and

extremely contentious debate over . . . which side of this debate has ‘truth’ on their side.

That is hardly the sort of issue that would be subject to verification based upon a core of

objective evidence.” (internal quotation marks omitted)); cf. Padnes v. Scios Nova Inc.,

No C 95-1693, 1996 WL 539711 (N.D. Cal. Sept. 18, 1996) (“Medical researchers may

13
well differ with respect to what constitutes acceptable testing procedures, as well as how

best to interpret data garnered under various protocols. The securities laws do not impose

a requirement that companies report only information from optimal studies, even if

scientists could agree on what is optimal.” (internal citation omitted)).

Where, as here, a statement is made as part of an ongoing scientific discourse

about which there is considerable disagreement, the traditional dividing line between fact

and opinion is not entirely helpful. It is clear to us, however, that while statements about

contested and contestable scientific hypotheses constitute assertions about the world that

are in principle matters of verifiable “fact,” for purposes of the First Amendment and the

laws relating to fair competition and defamation, they are more closely akin to matters of

opinion, and are so understood by the relevant scientific communities. In that regard, it is

relevant that plaintiff does not allege that the data presented in the article were fabricated

or fraudulently created. If the data were falsified, the fraud would not be easily detectable

by even the most informed members of the relevant scientific community. Rather,

plaintiff alleges that the inferences drawn from those data were the wrong ones, and that

competent scientists would have included variables that were available to the defendant

authors but that were not taken into account in their analysis. But when the conclusions

reached by experiments are presented alongside an accurate description of the data taken

into account and the methods used, the validity of the authors’ conclusions may be

assessed on their face by other members of the relevant discipline or specialty.

14
We therefore conclude that, to the extent a speaker or author draws conclusions

from non-fraudulent data, based on accurate descriptions of the data and methodology

underlying those conclusions, on subjects about which there is legitimate ongoing

scientific disagreement, those statements are not grounds for a claim of false advertising

under the Lanham Act. Here, ONY has alleged false advertising not because any of the

data presented were incorrect but because the way they were presented and the

conclusions drawn from them were allegedly misleading. Even if the conclusions authors

draw from the results of their data could be actionable, such claims would be weakest

when, as here, the authors readily disclosed the potential shortcomings of their

methodology and their potential conflicts of interest.5

Our conclusion that the article’s contents are not actionable under the Lanham Act

also leads us to conclude that the statements are not actionable under New York’s General

Business Law § 349 or New York state common law. In determining the extent of its

defamation and consumer protection laws, New York follows the same facts-andcircumstances approach laid out by the Supreme Court in Milkovich. See Immuno AG. v.

Moor-Jankowski, 77 N.Y.2d 235, 240, 244-45 (1991) (dismissing a libel suit against the

5

 To the extent plaintiff alleges harm arising from the relationship between the

authors and Chiesi and Cornerstone, we agree with the district court that the disclosure of

a conflict of interest, which was included in the article’s original publication, suffices to

put a reasonable reader on notice that the article’s conclusions may have been influenced

by the authors’ professional associations.

15
editor of a scientific journal, in light of Milkovich, because the allegedly libelous

statements were protected opinion). Our conclusion that what is non-actionable opinion

under the Lanham Act is also non-actionable as a New York tort or under General

Business Law § 349 is buttressed by the Court of Appeals’s statement that “the protection

afforded by the guarantees of free press and speech in the New York Constitution is often

broader than the minimum required by the Federal Constitution.” Id. at 249 (internal

quotation marks omitted). In other words, New York law is, if anything, more protective

of free speech interests and less expansive in permitting causes of action based on speech,

than federal law. There is thus no reason to believe that the New York Court of Appeals

would interpret state law to provide for more expansive liability than does the Lanham

Act.

We therefore conclude that the contents of the article are non-actionable scientific

conclusions to which neither the Lanham Act, New York General Business Law § 349,

nor New York’s common law tort of injurious falsehood apply. Because our decision

rests entirely on our conclusion about the non-actionability of the article’s contents, we

need not reach the district court’s independent holding that it lacked personal jurisdiction

over the physician defendants.6

6

 Although we traditionally treat personal jurisdiction as a threshold question to be

addressed prior to consideration of the merits of a claim, see In re Rationis Enters., Inc. of

Pan., 261 F.3d 264, 267-68 (2d Cir. 2001), that practice is prudential and does not reflect

a restriction on the power of the courts to address legal issues. In cases involving

16
II. Claims Arising out of the Distribution of the Article’s Conclusions

Plaintiff separately alleges that, by touting and distributing the article’s findings

for promotional purposes, Chiesi and Cornerstone tortiously interfered with its

prospective economic advantage in contracting with hospitals and other health-care

providers. It is important to note that plaintiff does not allege, nor did it at any point

during the proceedings before the district court seek to amend its complaint to allege, that

the promotional materials misstated the article’s conclusions. Thus, plaintiff’s objection is

not that Chiesi and Cornerstone distorted the article’s findings; rather, its theory is that by

presenting accurately the article’s allegedly inaccurate conclusions, Chiesi and

Cornerstone committed a separate tort, for which plaintiff is entitled to relief. 

We are therefore presented with a much easier case than we would be if a plaintiff

alleged that a defendant distorted an article’s findings in its promotional materials. On

these facts, we conclude that the district court did not err in dismissing plaintiff’s tortious

interference claim with prejudice in light of its correct conclusions that (a) the article

“multiple defendants – over some of whom the court indisputably has personal

jurisdiction – in which all defendants collectively challenge the legal sufficiency of the

plaintiff’s cause of action,” we have proceeded directly to the merits on a motion to

dismiss, Chevron Corp. v. Naranjo, 667 F.3d 232, 246 n.17 (2d Cir. 2012), and we do so

here. We have noted that this course of action is particularly appropriate where, as here,

“the personal jurisdictional challenges are based on factual allegations that are, in this

early posture, still under development.” Id.

17
itself was not actionable and (b) the tortious interference claim did not separately allege

any additional misleading statements. 

CONCLUSION

For the foregoing reasons, the judgment of the district court is hereby AFFIRMED.

18